All PlexusDx medications are compounded in licensed 503A compounding pharmacies, which operate under strict federal pharmaceutical standards and state oversight
GLP-1 for weight loss has emerged as a groundbreaking approach in the battle against obesity, which affects approximately 1 in 8 people worldwide
Personalization Through Genetic Testing PlexusDx offers the Precision Peptide Genetic Test, which examines individual variations in GLP-1 receptor pathways and cardiovascular risk genes
This adaptation presents a targetable vulnerability whereby the functional inhibition of this adaptive response greatly increased the effectiveness of 5FU across CRC models in vitro and in vivo
Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS, Hazen SL